Jonathan Milner founded Cambridge-based Abcam in 1998 after gaining a doctorate in Molecular Genetics. He identified the potential market opportunity in supplying high quality antibodies to support research in areas such as the human genome project. Abcam floated on the stock market in 2005 valued at £57.5m. It is now worth £857m.
Activity: Genetics research
Latest turnover: £122m
Five-year rise in turnover: 114%
No. of employees: 690
Five-year rise in employment: 222%